Genistein modulates the expression of NF-κB and MAPK (p-38 and ERK1/2), thereby attenuating d-Galactosamine induced fulminant hepatic failure in Wistar rats

Toxicology and Applied Pharmacology

Volumn 283, Issue 2, 2015, Pages 139-146

  Ganai, Ajaz A ^a   Khan, Athar A ^a   Malik, Zainul A ^a   Farooqi, Humaira ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Antioxidant; Apoptosis; Liver damage; Necrosis; Oxidative stress; Phytoestrogen

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYCLOOXYGENASE 2; GALACTOSAMINE; GENISTEIN; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NITRIC OXIDE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; FULMINANT HEPATIC FAILURE; HEPATITIS; HISTOPATHOLOGY; LIVER TOXICITY; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SINGLE DRUG DOSE; TREATMENT DURATION; WISTAR RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMICALLY INDUCED; DRUG EFFECTS; GENE EXPRESSION REGULATION; LIVER FAILURE, ACUTE; METABOLISM; PHYSIOLOGY; RANDOMIZATION; SIGNAL TRANSDUCTION;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

ANIMALS; GALACTOSAMINE; GENE EXPRESSION REGULATION; GENISTEIN; LIVER FAILURE, ACUTE; MALE; MAP KINASE SIGNALING SYSTEM; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RANDOM ALLOCATION; RATS; RATS, WISTAR;

EID: 84921860740     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2015.01.012     Document Type: Article

References (45)

1. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., Shibuya M., Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 1987, 262:5592-5595.
2. Appleby S.B., Ristimaki A., Neilson K., Narko K., Hla T. Structure of the human cyclo-oxygenase-2 gene. Biochem. J. 1994, 302(Pt 3):723-727.
3. Beauparlant P., Hiscott J. Biological and biochemical inhibitors of the NF-kappa B/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev. 1996, 7:175-190.
4. Brehe J.E., Burch H.B. Enzymatic assay for glutathione. Anal. Biochem. 1976, 74:189-197.
5. Buege J.A., Aust S.D. Microsomal lipid peroxidation. Methods Enzymol. 1978, 52:302-310.
6. Burkitt H.G., Young B., Heath J.W. Wheater's Functional Histology 1993.
7. Caldarelli A., Diel P., Vollmer G. Effect of phytoestrogens on gene expression of carbonic anhydrase II in rat uterus and liver. J. Steroid Biochem. Mol. Biol. 2005, 97:251-256.
8. Chan E.D., Riches D.W. IFN-gamma+LPS induction of iNOS is modulated by ERK, JNK/SAPK, and p38(mapk) in a mouse macrophage cell line. Am. J. Physiol. Cell Physiol. 2001, 280:C441-C450.
9. Chen G.Y., Nunez G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol. 2010, 10:826-837.
10. Crispe I.N. The liver as a lymphoid organ. Annu. Rev. Immunol. 2009, 27:147-163.
11. Decker K., Keppler D. Galactosamine hepatitis: key role of the nucleotide deficiency period in the pathogenesis of cell injury and cell death. Rev. Physiol. Biochem. Pharmacol. 1974, 77-106.
12. Dhiman R.K., Seth A.K., Jain S., Chawla Y.K., Dilawari J.B. Prognostic evaluation of early indicators in fulminant hepatic failure by multivariate analysis. Dig. Dis. Sci. 1998, 43:1311-1316.
13. Ecobichon D.J. The Basis of Toxicity Testing 1997, CRC press.
14. Ganai A.A., Jahan S., Ahad A., Abdin M.Z., Farooqi H. Glycine propionyl l-carnitine attenuates d-Galactosamine induced fulminant hepatic failure in Wistar rats. Chem. Biol. Interact. 2014, 214:33-40.
15. Ghosh S., Hayden M.S. New regulators of NF-kappaB in inflammation. Nat. Rev. Immunol. 2008, 8:837-848.
16. Goldwyn S., Lazinsky A., Wei H. Promotion of health by soy isoflavones: efficacy, benefit and safety concerns. Drug Metabol. Drug Interact. 2000, 17:261-289.
17. Jeong J.B., Hong S.C., Jeong H.J., Koo J.S. Anti-inflammatory effect of 2-methoxy-4-vinylphenol via the suppression of NF-kappaB and MAPK activation, and acetylation of histone H3. Arch. Pharm. Res. 2011, 34:2109-2116.
18. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34:637-650.
19. Kim J.K., Park G.M. Indirubin-3-monoxime exhibits anti-inflammatory properties by down-regulating NF-kappaB and JNK signaling pathways in lipopolysaccharide-treated RAW264.7 cells. Inflamm. Res. 2012, 61:319-325.
20. Kind P.R., King E.J. Estimation of plasma phosphatase by determination of hydrolysed phenol with amino-antipyrine. J. Clin. Pathol. 1954, 7:322-326.
21. Krakauer T. Molecular therapeutic targets in inflammation: cyclooxygenase and NF-kappaB. Curr. Drug Targets Inflamm. Allergy 2004, 3:317-324.
22. Kuzu N., Metin K., Dagli A.F., Akdemir F., Orhan C., Yalniz M., Ozercan I.H., Sahin K., Bahcecioglu I.H. Protective role of genistein in acute liver damage induced by carbon tetrachloride. Mediat. Inflamm. 2007, 2007:36381.
23. Lin A.W., Chang C.C., McCormick C.C. Molecular cloning and expression of an avian macrophage nitric-oxide synthase cDNA and the analysis of the genomic 5'-flanking region. J. Biol. Chem. 1996, 271:11911-11919.
24. Liu R.H., Hotchkiss J.H. Potential genotoxicity of chronically elevated nitric oxide: a review. Mutat. Res. 1995, 339:73-89.
25. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods (San Diego, Calif.) 2001, 25:402-408.
26. Matsuzaki Y., Koyama M., Hitomi T., Kawanaka M., Sakai T. Indole-3-carbinol activates the cyclin-dependent kinase inhibitor p15(INK4b) gene. FEBS Lett. 2004, 576:137-140.
27. Medzhitov R., Horng T. Transcriptional control of the inflammatory response. Nat. Rev. Immunol. 2009, 9:692-703.
28. Messina M.J., Loprinzi C.L. Soy for breast cancer survivors: a critical review of the literature. J. Nutr. 2001, 131:3095S-3108S.
29. Messina S., Bitto A., Aguennouz M., Vita G.L., Polito F., Irrera N., Altavilla D., Marini H., Migliorato A., Squadrito F., Vita G. The soy isoflavone genistein blunts nuclear factor kappa-B, MAPKs and TNF-alpha activation and ameliorates muscle function and morphology in mdx mice. Neuromuscul. Disord. 2011, 21:579-589.
30. Mohamed Salih S., Nallasamy P., Muniyandi P., Periyasami V., Carani Venkatraman A. Genistein improves liver function and attenuates non-alcoholic fatty liver disease in a rat model of insulin resistance. J. Diabetes 2009, 1:278-287.
31. Park C.E., Yun H., Lee E.B., Min B.I., Bae H., Choe W., Kang I., Kim S.S., Ha J. The antioxidant effects of genistein are associated with AMP-activated protein kinase activation and PTEN induction in prostate cancer cells. J. Med. Food 2010, 13:815-820.
32. Pasparakis M. Regulation of tissue homeostasis by NF-kappaB signalling: implications for inflammatory diseases. Nat. Rev. Immunol. 2009, 9:778-788.
33. Piva R., Belardo G., Santoro M.G. NF-kappaB: a stress-regulated switch for cell survival. Antioxid. Redox Signal. 2006, 8:478-486.
34. Pushpavalli G., Veeramani C., Pugalendi K.V. Influence of Piper betle on hepatic marker enzymes and tissue antioxidant status in D-galactosamine-induced hepatotoxic rats. J. Basic Clin. Physiol. Pharmacol. 2008, 19:131-150.
35. Reitman S., Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am. J. Clin. Pathol. 1957, 28:56-63.
36. Rusin A., Krawczyk Z., Grynkiewicz G., Gogler A., Zawisza-Puchalka J., Szeja W. Synthetic derivatives of genistein, their properties and possible applications. Acta Biochim. Pol. 2010, 57:23-34.
37. Sarkar F.H., Li Y. Soy isoflavones and cancer prevention. Cancer Investig. 2003, 21:744-757.
38. Seriolo B., Paolino S., Sulli A., Fasciolo D., Cutolo M. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann. N. Y. Acad. Sci. 2006, 1069:414-419.
39. Tacke F., Luedde T., Trautwein C. Inflammatory pathways in liver homeostasis and liver injury. Clin. Rev. Allergy Immunol. 2009, 36:4-12.
40. Veres B., Radnai B., Gallyas F., Varbiro G., Berente Z., Osz E., Sumegi B. Regulation of kinase cascades and transcription factors by a poly(ADP-ribose) polymerase-1 inhibitor, 4-hydroxyquinazoline, in lipopolysaccharide-induced inflammation in mice. J. Pharmacol. Exp. Ther. 2004, 310:247-255.
41. Wang H.K. The therapeutic potential of flavonoids. Expert Opin. Investig. Drugs 2000, 9:2103-2119.
42. Wills P.J., Asha V.V. Protective effect of Lygodium flexuosum (L.) Sw. (Lygodiaceae) against D-galactosamine induced liver injury in rats. J. Ethnopharmacol. 2006, 108:116-123.
43. Xiong Q., Hase K., Tezuka Y., Namba T., Kadota S. Acteoside inhibits apoptosis in D-galactosamine and lipopolysaccharide-induced liver injury. Life Sci. 1999, 65:421-430.
44. Yellayi S., Zakroczymski M.A., Selvaraj V., Valli V.E., Ghanta V., Helferich W.G., Cooke P.S. The phytoestrogen genistein suppresses cell-mediated immunity in mice. J. Endocrinol. 2003, 176:267-274.
45. Zhang Y., Chen W.F., Lai W.P., Wong M.S. Soy isoflavones and their bone protective effects. Inflammopharmacology 2008, 16:213-215.